Sign Up
OverviewAPI
The global pneumococcal vaccine market is projected to grow at a 6.26% CAGR from 2022 to 2028, reaching a valuation of 13.78 billion by 2028. The market's growth is driven by increased global awareness of pneumococcal diseases and vaccination initiatives, as well as pharmaceutical innovations, despite challenges like economic disparities in vaccine accessibility and supply chain efficiency.

Ask a question